Exelixis’s Strategic Oncology Expansion and Pipeline Innovations Justify Buy Rating
I'm PortAI, I can summarize articles.
William Blair analyst Andy Hsieh maintains a Buy rating on Exelixis (EXEL) stock, citing the company's strategic oncology expansion and pipeline innovations. Exelixis aims to enhance its oncology presence through its Cabometyx franchise and new assets like zanzalintinib. The company is expanding treatment capabilities for various cancers and developing new programs, including antibody-drug-conjugates and a SSTR2 agonist. These initiatives are expected to offset Cabometyx's patent expiration and support long-term growth. Hsieh has a 14.5% average return and a 47.17% success rate on stock recommendations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments